Thomas Beck is listed as a director on 6 SEC Form D filings by 3 issuers between Jul 2014 and Dec 2019: Symbiomix Therapeutics, LLC (Newark, NJ — pharmaceuticals — 2014–2016; $19.5M reported sold to 5 investors), Promentis Pharmaceuticals, Inc. (Milwaukee, WI — pharmaceuticals — 2019; $17.6M reported sold to 8 investors) and Akriveia Therapeutics, LLC (Skillman, NJ — biotechnology — 2016–2018; $4.5M reported sold to 1 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 5 years. Across those companies the filings report $41.6M sold in total.
Listed alongside Klaus Veitinger (4 shared filings), Rishi Gupta (3 shared filings), Robert Jacks (3 shared filings), Ben Auspitz (2 shared filings), Benjamin Auspitz (2 shared filings) and 10 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Thomas. Each name links to their own page.
1 of the issuers belongs to the sponsor group Akriveia (2 issuers, $3.2M reported sold, 2016–2023).
What this means A sponsor group is one team that sets up a new company for each deal. Akriveia has 2 companies on file and $3.2M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 6 public filings for Thomas Beck and found 7 differences, 1 worth asking the sponsor about: Form D filed 432 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.